Registered business in FR. Official registry identity, filed financial evidence and a rounded indicative valuation range on one indexed company profile.
Historical rounded range based on the latest available public filing for fiscal year 2023. This is not a current market value or asking price.
Based on filed company accountsCreate a free account to see the detailed curve, the factors that influence it, and an indicative five-year outlook.
Free account · private workspace
Each step adds evidence that narrows the range. Public filings are a starting point. Connected accounts, owner context and method review make the valuation more useful for real decisions.
Continue privately and connect your accounting data to make the graph more accurate.
Continue as ownerTrack the buying status below. If the owner opens a process, you can request a conversation and review the details before making an offer.
View buying statusYou have seen the historical curve. Create a free account to explore a private five-year value scenario and the assumptions behind it.
The historical indicative range for BOCAGENESE uses the latest available public filing and sector calibration. It is not a current market value or asking price; current owner or advisor data is needed for a full valuation.
This company is not currently listed for sale on Upswitch.
This is an estimate, not an asking price. It is based on dated public sources and is not an owner forecast, offer, investment advice, or confirmation that the company is for sale.
Request verified control to add current figures, improve the profile and manage what happens next. We verify ownership before granting access.
Operating as a business in NACE sector 46.73, BOCAGENESE is registered in France. The company was founded in 2013, incorporated as a 5599.
BOCAGENESE is listed in French National Business Register (RNE/INPI) under registry number 791275928. The public employee band is 01, a useful triage field for banks, credit analysts, and M&A acquirers. This profile consolidates official annual accounts into one indexable company dossier.
Within the French NACE 46.73 cluster, public-record data is filed annually via the national company registry.
Across the 2017-2023 window revenue has more than doubled, moving from €145,465 to €544,930.
The most recent annual filing covers 2023 (period end 2023-06-30).
The historical indicative range for BOCAGENESE is refreshed when new regulator-filed data becomes available; until then it remains a filing-year research aid, not a current market value.
Public regulator-filed figures across 3 years.
Fiscal year | Revenue | EBITDA | Total assets | Equity | Filing |
|---|---|---|---|---|---|
| 202330 Jun 2023 | €544,930 | - | €517,137 | €68,338 | - |
| 201930 Jun 2019 | €472,377 | - | €517,816 | €9,334 | - |
| 201730 Jun 2017 | €145,465 | - | €330,110 | -€134,843 | - |
BOCAGENESE was founded in 2013 and is registered with French National Business Register (RNE/INPI), incorporated as a 5599.
BOCAGENESE is registered under NACE 46.73: NACE 46.73. That places the business within the French cluster for this activity.
The most recently filed annual accounts cover fiscal year 2023 (period end 2023-06-30), publicly available via French National Business Register (RNE/INPI).
This page shows a rounded historical indicative range for BOCAGENESE, based on the latest available public filing for fiscal year 2023. It is not a current market value, asking price, certified or statutory valuation, or financial, investment, tax or legal advice. Verify current figures before relying on it for any decision or transaction.
Company identity and public facts are reused from the official or licensed source named on this page, with its filing or update date. Upswitch estimates remain distinct from source facts and do not imply endorsement by the registry. Natural-person enterprises are excluded from public valuation pages, and public registry personal data is not used for direct marketing.
Connected to this company and want something corrected? Request a correction or removal · Privacy policy · Terms & conditions · Data sources & evidence
